LEGEND BIOTECH CORPORA

Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights

12 نوفمبر 2024 07:00:01 بحسب Nasdaq GlobeNewswire

Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

07 نوفمبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma

05 نوفمبر 2024 09:10:00 بحسب Nasdaq GlobeNewswire

Legend Biotech Appoints Alan Bash as President of CARVYKTI®

04 نوفمبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results

24 أكتوبر 2024 08:00:01 بحسب Nasdaq GlobeNewswire

Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

03 أكتوبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line

27 سبتمبر 2024 16:35:00 بحسب Nasdaq GlobeNewswire

Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

20 أغسطس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights

09 أغسطس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors

08 أغسطس 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024

26 يوليو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results

10 يوليو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma

02 يوليو 2024 08:00:00 بحسب Nasdaq GlobeNewswire